Biotech Startups

1 investor

R3 Vascular develops bioresorbable vascular scaffolds made from a proprietary polymer using a proprietary manufacturing process. It operates in the medical device field for vascular treatment.

1 investor

1 investor

Ractigen Therapeutics develops proprietary RNA delivery platforms for oligonucleotide therapeutics, enabling treatment of previously unreachable tissues and organs in the CNS and beyond the liver. The company's platforms support clinical development of RNA-based therapies through simplified manufacturing processes.

1 investor

Radiogenesis builds an end-to-end computational pipeline that uses AI, protein engineering, and radiochemistry to design and optimize novel targeted radioligand therapies for patients with metastatic cancers. Its platform generates and validates candidate molecules through a lab-in-the-loop process and is isotope agnostic, starting with Actinium-225 and Lutetium-177.

1 investor

Radius is a pharmaceutical company that provides funding through Investigator Initiated Study grants and independent Medical Education grants supporting clinical research and continuing medical education for healthcare professionals in therapeutic areas related to its products.

1 investor

Radix Labs builds operating-system software for biology laboratories to run and automate their lab workflows. It serves life-science and biotech labs.

1 investor

RAINBOW develops regenerative medicine products for brain repair, using autologous mesenchymal stem cells (MSCs) cultured from a patient's own bone marrow. The company works on custom cell-based therapies aimed at treating brain damage.

1 investor

Rakuten Medical is a global biotechnology company that develops and commercializes precision cell-targeting photoimmunotherapy treatments for cancer using its proprietary Alluminox platform. The company focuses on creating innovative cancer treatment options and bringing them to patients worldwide.

1 investor

RA Marketing PR is a marketing and positioning agency for life science organizations that combines human expertise with AI tools to inform commercial strategy and market positioning decisions.

1 investor

Rancho Biosciences provides biomedical data services covering strategy, curation, bioinformatics, engineering, analytics, and AI-ready data products for life sciences and pharmaceutical R&D teams. It delivers harmonized, annotated datasets—including single-cell, spatial, and oncology data—to support research from discovery through clinical development.

1 investor

Ranomics offers a programmatic "wet lab as an API" for protein binder design workflows, letting teams submit computationally designed candidates (from tools like RFdiffusion, ProteinMPNN, and BoltzGen) for high-throughput screening and receive enriched hits and NGS data. It provides yeast surface display, mammalian display, and deep mutational scanning as library-scale triage upstream of per-sequence biophysics, serving AI-driven protein and antibody design teams.

1 investor

Rapafusyn develops molecular glue therapeutics using its RapaGlue platform of non-degrading macrocyclic compounds designed to modulate hard-to-drug intracellular and transmembrane protein targets. Its AI-enabled discovery approach and DNA-encoded library support an early-stage pipeline across oncology, immunology and inflammation, and renal disease, including a lead program in acute kidney injury.</parameter> <parameter name="hq_city">Baltimore

1 investor

Rapid Genomics, part of LGC Biosearch Technologies, provides targeted sequencing and genotyping solutions for plant, livestock, and aquaculture breeding programs. Its services support marker discovery, SNP discovery, parentage testing, and quality control to improve trait development and breeding efficiency.

1 investor

Rapid-myco Technologies develops bacteriophage-based diagnostic tests for detecting mycobacterial infections in humans and livestock, with rapid turnaround times. The company offers tests for diseases including Johne's disease in livestock and tuberculosis in humans and animals.

1 investor

Rapid Nexus Nanotech Wound Solutions develops a regenerative medical device technology (Hemastyl) that aims to repair nerves, muscle, and vasculature to heal chronic non-healing wounds and prevent amputations. It targets patients with diabetes, trauma, and peripheral vascular disease in the peripheral neuropathy and diabetic foot ulcer markets.

1 investor

Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function. The company targets the underlying mechanism of protein hyperphosphorylation that drives cancer progression.

1 investor

RareTerra uses biotechnology to produce rare earth metals domestically in the United States, aiming to lower costs and eliminate toxic chemicals while recycling critical minerals. Its materials target clean energy, communications, and consumer technology supply chains.

1 investor

RasCal Therapeutics develops targeted cancer therapies aimed at previously "untargetable" mutations that drive some of the deadliest cancers, using novel mechanisms intended to work alongside conventional treatments, targeted therapies, and immunotherapies. The company is conducting human clinical trials of its lead anti-cancer compound.

1 investor

Ravel develops an AI-powered platform for early disease detection by analyzing epigenomic profiles in cell-free DNA to identify cellular destruction markers.

1 investor

RAWGA develops plant-based ingredients for the wellness, nutraceutical, and cosmetics industries, led by VC-H1, a plant-derived collagen peptide intended as an alternative to animal-derived collagen. Based in South Korea, it supplies raw materials and finished products for health supplements and beauty applications.

1 investor

Restoring vision through optogenetics.

1 investor

RayBalance develops a proprietary, non-reformulation platform that treats the subcutaneous injection administration site as a delivery-performance variable to improve absorption predictability without altering a partner's drug product. It targets pharmaceutical companies, biosimilar manufacturers, and medical device companies working on follow-on/biosimilar differentiation, lifecycle strategy, and IV-to-SC transition.

1 investor

RBL Ventures is a venture firm and company-building partner that works with scientific founders, physicians, and researchers to turn biomedical discoveries into biotechnology companies. Based in the Texas Medical Center ecosystem in Houston, it provides early-stage capital, operational expertise, and infrastructure to advance medicines addressing unmet patient needs.

1 investor